GlaxoSmithKline (LON:GSK)‘s stock had its “overweight” rating reissued by research analysts at Barclays in a research report issued on Friday. They currently have a GBX 1,650 ($23.14) target price on the stock. Barclays’ price target would suggest a potential upside of 27.81% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. Investec lowered shares of GlaxoSmithKline to a “hold” rating and reduced their price objective for the company from GBX 1,800 ($25.24) to GBX 1,390 ($19.49) in a research note on Monday, November 6th. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Jefferies Group reduced their price objective on shares of GlaxoSmithKline from GBX 1,700 ($23.84) to GBX 1,540 ($21.59) and set a “buy” rating for the company in a research note on Tuesday, October 31st. UBS Group set a GBX 1,550 ($21.73) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a report on Thursday. Finally, Berenberg Bank dropped their target price on shares of GlaxoSmithKline from GBX 1,760 ($24.68) to GBX 1,705 ($23.91) and set a “buy” rating on the stock in a report on Thursday. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,291 ($18.10) on Friday. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($17.32) and a 52 week high of GBX 1,724.50 ($24.18). The stock has a market cap of $64,010.00 and a price-to-earnings ratio of 4,164.52.

In other GlaxoSmithKline news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). Also, insider Sir Roy Anderson purchased 562 shares of GlaxoSmithKline stock in a transaction on Wednesday, February 7th. The stock was purchased at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). In the last three months, insiders purchased 581 shares of company stock worth $743,284.

TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline (GSK) Stock Rating Reaffirmed by Barclays” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/11/glaxosmithkline-gsk-stock-rating-reaffirmed-by-barclays.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.